AR079495A1 - Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a - Google Patents
Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10aInfo
- Publication number
- AR079495A1 AR079495A1 ARP100104668A ARP100104668A AR079495A1 AR 079495 A1 AR079495 A1 AR 079495A1 AR P100104668 A ARP100104668 A AR P100104668A AR P100104668 A ARP100104668 A AR P100104668A AR 079495 A1 AR079495 A1 AR 079495A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- alkyl
- formula
- provides
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Valve Device For Special Equipments (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente se dirige a compuestos, que son inhibidores de la enzima PDE10A. Proporciona una composicion farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto y un portador farmacéuticamente aceptable. La presente también proporciona procesos para la preparacion de los compuestos de la formula 1. La presente además proporciona un método de tratar un sujeto que padece de un trastorno neurodegenerativo que comprende la administracion al sujeto de una cantidad terapéuticamente efectiva de un compuesto de la formula 1. La presente también proporciona un método para tratar a un sujeto que padece de adiccion a las drogas que comprende la administracion a un sujeto de una cantidad terapéuticamente efectiva de un compuesto de la formula 1. La presente además proporciona un método para tratar a un sujeto que padece de un trastorno psiquiátrico que comprende la administracion al sujeto de una cantidad terapéuticamente efectiva de un compuesto de la formula 1. Reivindicacion 1: Un compuesto que tiene la estructura 1 en donde HET1 es un grupo heteroaromáticos de 2 que contiene de 2 a 4 átomos de nitrogeno: en donde Y puede ser N o CH, Z puede ser N o C, y en donde HET1 puede sustituirse opcionalmente con hasta tres sustituyentes R2-R4 individualmente seleccionados de hidrogeno, alquilo C1-6 halogeno; ciano, haloalquilo C1-6; arilo, alcoxi e hidroxialquilo C1-6, y en donde * denota el punto de union, HET2 es un grupo heteroaromático de la formula 3 o 4: en donde Y puede ser N, S, O o CH, X puede ser N o CH, y en donde HET2 puede sustituirse opcionalmente con hasta tres sustituyentes R5, R6 y R7 individualmente seleccionados de hidrogeno, alquilo C1-6 halogeno; ciano, haloalquilo C1-6; arilo, alcoxi e hidroxialquilo C1-6, y en donde * denota el punto de union, -L- es un enlazante seleccionado de -S-CH2-, -CH2-S-, -CH2-CH2-, -CH=CH-, y C=C R1 se selecciona de H, alquilo C1-6 alquil C1-6 cicloalquilo C3-8; hidroxialquilo C1-6, CH2CN, CH2C(O)NH2, arilalquilo C1-6, y alquil C1-6- heterocicloalquilo, y tautomeros y sales de adicion de ácidos farmacéuticamente aceptables de los mismos, y formas polimorficas de los mismos, siempre que el compuesto no sea 2-(5-fenil-1H-imidazol-2-ilmetilsulfanil)-1H-benzoimidazol o 2-(5-fenil-1H-imidazol-2-il-sulfanil-metil)-1H-benzoimidazol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200901339 | 2009-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079495A1 true AR079495A1 (es) | 2012-02-01 |
Family
ID=44246808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104668A AR079495A1 (es) | 2009-12-17 | 2010-12-16 | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9096589B2 (es) |
| EP (1) | EP2513107B1 (es) |
| JP (1) | JP5901535B2 (es) |
| KR (1) | KR101803984B1 (es) |
| CN (1) | CN102741250B (es) |
| AR (1) | AR079495A1 (es) |
| AU (1) | AU2010333435B2 (es) |
| BR (1) | BR112012017205A2 (es) |
| CA (1) | CA2783726A1 (es) |
| CO (1) | CO6612245A2 (es) |
| CR (1) | CR20120319A (es) |
| CY (1) | CY1115843T1 (es) |
| DK (1) | DK2513107T3 (es) |
| DO (1) | DOP2012000165A (es) |
| EA (1) | EA023663B1 (es) |
| ES (1) | ES2514647T3 (es) |
| GE (1) | GEP20156241B (es) |
| GT (1) | GT201200171A (es) |
| HK (1) | HK1177208A1 (es) |
| HR (1) | HRP20140898T1 (es) |
| IL (1) | IL220327A (es) |
| MA (1) | MA33922B1 (es) |
| MX (1) | MX2012006969A (es) |
| MY (1) | MY158197A (es) |
| NZ (1) | NZ600260A (es) |
| PL (1) | PL2513107T3 (es) |
| PT (1) | PT2513107E (es) |
| RS (1) | RS53579B1 (es) |
| SG (1) | SG181674A1 (es) |
| SI (1) | SI2513107T1 (es) |
| SM (1) | SMT201400158B (es) |
| TN (1) | TN2012000271A1 (es) |
| TW (1) | TWI485151B (es) |
| UA (1) | UA108487C2 (es) |
| WO (1) | WO2011072694A1 (es) |
| ZA (1) | ZA201204419B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基***衍生物 |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| WO2011150156A2 (en) * | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| JO3089B1 (ar) * | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| US8552045B2 (en) | 2010-11-19 | 2013-10-08 | H. Lundbeck A/S | Tricyclic imidazole compounds as PDE10 inhibitors |
| CA2824047C (en) | 2011-01-11 | 2019-06-18 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CN103476757A (zh) | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| UA108711C2 (uk) * | 2011-09-19 | 2015-05-25 | Ф. Хоффманн-Ля Рош Аг | Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a |
| WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
| BR112014031798A2 (pt) * | 2012-06-19 | 2017-06-27 | Sunovion Pharmaceuticals Inc | compostos de heteroaril e métodos de uso destes |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9790203B2 (en) * | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| FR2824065A1 (fr) | 2001-04-26 | 2002-10-31 | Neuro3D | Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
| NZ540167A (en) | 2002-10-30 | 2007-06-29 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| CA2530114A1 (en) | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| MXPA05013822A (es) | 2003-06-30 | 2006-02-28 | Altana Pharma Ag | Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer. |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| JP2007523152A (ja) | 2004-02-18 | 2007-08-16 | ファイザー・プロダクツ・インク | キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体 |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| WO2006028957A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| WO2008006372A1 (en) * | 2006-07-10 | 2008-01-17 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| UA102693C2 (ru) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基***衍生物 |
| TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
-
2010
- 2010-12-10 TW TW099143184A patent/TWI485151B/zh not_active IP Right Cessation
- 2010-12-15 JP JP2012543475A patent/JP5901535B2/ja not_active Expired - Fee Related
- 2010-12-15 EA EA201290516A patent/EA023663B1/ru not_active IP Right Cessation
- 2010-12-15 CA CA2783726A patent/CA2783726A1/en not_active Abandoned
- 2010-12-15 BR BR112012017205A patent/BR112012017205A2/pt not_active Application Discontinuation
- 2010-12-15 SG SG2012043519A patent/SG181674A1/en unknown
- 2010-12-15 WO PCT/DK2010/050341 patent/WO2011072694A1/en active Application Filing
- 2010-12-15 UA UAA201207960A patent/UA108487C2/uk unknown
- 2010-12-15 PT PT107982555T patent/PT2513107E/pt unknown
- 2010-12-15 RS RSP20140527 patent/RS53579B1/en unknown
- 2010-12-15 MA MA35063A patent/MA33922B1/fr unknown
- 2010-12-15 ES ES10798255.5T patent/ES2514647T3/es active Active
- 2010-12-15 CN CN201080063808.4A patent/CN102741250B/zh not_active Expired - Fee Related
- 2010-12-15 EP EP10798255.5A patent/EP2513107B1/en active Active
- 2010-12-15 SI SI201030765T patent/SI2513107T1/sl unknown
- 2010-12-15 AU AU2010333435A patent/AU2010333435B2/en not_active Ceased
- 2010-12-15 NZ NZ600260A patent/NZ600260A/en not_active IP Right Cessation
- 2010-12-15 MX MX2012006969A patent/MX2012006969A/es active IP Right Grant
- 2010-12-15 DK DK10798255.5T patent/DK2513107T3/da active
- 2010-12-15 KR KR1020127015655A patent/KR101803984B1/ko active IP Right Grant
- 2010-12-15 GE GEAP201012785A patent/GEP20156241B/en unknown
- 2010-12-15 MY MYPI2012002598A patent/MY158197A/en unknown
- 2010-12-15 US US13/513,867 patent/US9096589B2/en not_active Expired - Fee Related
- 2010-12-15 PL PL10798255T patent/PL2513107T3/pl unknown
- 2010-12-16 AR ARP100104668A patent/AR079495A1/es unknown
-
2012
- 2012-05-29 TN TNP2012000271A patent/TN2012000271A1/en unknown
- 2012-05-31 GT GT201200171A patent/GT201200171A/es unknown
- 2012-06-12 CR CR20120319A patent/CR20120319A/es unknown
- 2012-06-12 IL IL220327A patent/IL220327A/en not_active IP Right Cessation
- 2012-06-13 CO CO12099152A patent/CO6612245A2/es active IP Right Grant
- 2012-06-14 DO DO2012000165A patent/DOP2012000165A/es unknown
- 2012-06-15 ZA ZA2012/04419A patent/ZA201204419B/en unknown
-
2013
- 2013-04-15 HK HK13104532.2A patent/HK1177208A1/xx not_active IP Right Cessation
-
2014
- 2014-09-19 HR HRP20140898AT patent/HRP20140898T1/hr unknown
- 2014-09-26 CY CY20141100789T patent/CY1115843T1/el unknown
- 2014-10-29 SM SM201400158T patent/SMT201400158B/xx unknown
-
2015
- 2015-06-25 US US14/749,754 patent/US9669029B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR072199A1 (es) | Derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
| AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR083926A1 (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR067946A1 (es) | Imidazoles biciclicos fusionados | |
| CL2009001152A1 (es) | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| JP2013536188A5 (es) | ||
| AR075253A1 (es) | Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene. | |
| PE20090216A1 (es) | Compuestos triazolil aminopirimidina | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| AR075951A1 (es) | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| AR058329A1 (es) | Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |